Healthcare & Pharmaceutical Market Research in the USA

    BioNixus is a healthcare and pharmaceutical market research company in the USA, designing and executing primary studies for pharma and biotech teams launching or growing in the US market. Our research covers HCP insights, KOL mapping, payer and PBM formulary research, patient journey studies, and HEOR evidence — purpose-built for the US's multi-payer, FDA-regulated healthcare environment.

    Looking for pharmaceutical-specific research? US pharmaceutical market research covers HCP surveys, PBM payer research, IRA impact studies, and market access strategy.

    Best healthcare market research company in USA

    BioNixus is a leading healthcare market research company in the USA, specialising in IRB-compliant HCP surveys, KOL mapping, PBM payer research, and health outcomes studies aligned with FDA and CMS requirements.

    • HCP and Physician SurveysIRB-compliant physician surveys and in-depth interviews across US academic medical centres, community IDN networks, and specialty practices in oncology, cardiovascular, immunology, and rare disease.
    • Payer and Formulary ResearchPBM formulary committee interviews, Medicare Part B/D payer studies, and hospital P&T committee research — covering the payer dynamics that determine real-world US market access.
    • Health Outcomes and HEORReal-world evidence generation, patient-reported outcome studies, cost-effectiveness research, and pre-ICER evidence strategy supporting US market access and reimbursement dossiers.

    BioNixus delivers primary healthcare market research in the USA with IRB-compliant methodologies, covering HCP surveys, payer and PBM research, KOL mapping, and health outcomes studies.

    Therapeutic areas and research segments in the USA

    Oncology and hematology

    KOL mapping at NCI cancer centres (MSKCC, MD Anderson, Dana-Farber), physician research across immuno-oncology, targeted therapy, and CAR-T therapy adoption

    Biologics and biosimilars

    Biologic market access research, biosimilar substitution attitudes at US hospital and retail pharmacy, PBM formulary strategy for interchangeable biosimilars

    GLP-1 and metabolic / diabetes

    Semaglutide and tirzepatide adoption dynamics, obesity treatment coverage research, Medicare Part D formulary access, IRA-linked pricing intelligence

    Cardiovascular

    PCSK9 inhibitor access research, SGLT2 and HFrEF treatment algorithm studies, IRA-negotiated cardiovascular product impact, payer prior authorization patterns

    Rare disease and gene therapy

    Orphan drug market access research, gene therapy one-time payment model studies, rare disease specialist KOL mapping, patient advocacy network research

    Immunology and JAK inhibitors

    Humira biosimilar market impact research, IL-17/23 and JAK inhibitor formulary dynamics, PBM step therapy policy research across rheumatology and dermatology

    Medical devices and diagnostics

    Device adoption research, hospital value analysis committee (VAC) behavior, FDA 510(k) and PMA pathway intelligence, IVD and companion diagnostic market research

    Pharmacovigilance and post-market

    FDA post-marketing surveillance research, REMS program awareness studies, healthcare provider pharmacovigilance behavior across specialty care settings

    Consumer health and OTC

    Consumer health brand tracking, OTC switch research, pharmacy category management studies, FMCG and wellness market research for US consumer segments

    Research audiences: who we reach in the USA

    HCPs — physicians and specialists

    Prescribing oncologists, cardiologists, endocrinologists, rheumatologists, and primary care physicians across US academic medical centres, community practices, and integrated delivery networks (IDNs).

    KOLs — key opinion leaders

    US academic and clinical thought leaders at Mayo Clinic, Cleveland Clinic, MSKCC, Johns Hopkins, UCSF, and NCI-designated cancer centres. BioNixus maps influence networks by therapeutic area and commercial priority.

    Patients and caregivers

    Patient journey studies, quality-of-life research, adherence drivers and barriers, patient support program needs — conducted with HIPAA-compliant, IRB-approved protocols and documented informed consent.

    Payers and PBM medical directors

    PBM pharmacy directors, Medicare plan medical directors, and commercial insurer pharmacy benefit managers who determine formulary placement, coverage criteria, and prior authorization policies.

    Hospital P&T committee members

    Pharmacy and therapeutics committee chairs, clinical pharmacists, and hospital formulary decision-makers at major IDN and GPO-affiliated hospital systems across US regions.

    Healthcare research methodology

    Every BioNixus US healthcare study begins with a single commercial or access decision — formulary strategy, KOL prioritization, PBM negotiation preparation, or launch sequencing. Instruments, sample frames, and analysis plans are designed backward from that decision.

    We combine quantitative rigor (structured HCP surveys, market segmentation, treatment algorithm modeling) with qualitative depth (in-depth interviews, virtual advisory boards, paired physician-payer modules) so leadership sees both the metric and the reason behind it.

    Fieldwork follows US healthcare research standards: IRB-compliant protocols under 45 CFR Part 46, HIPAA/HITECH-compliant data handling, screened and verified respondents, documented informed consent, and de-identified reporting. For advisory board and real-world evidence programs, BioNixus designs sessions compatible with FDA and CMS evidence standards.

    Regulatory and market access depth: FDA, CMS, PBMs, and IRA

    US pharmaceutical market access is genuinely multi-stakeholder. FDA approval grants market authorisation — but commercial outcomes depend on PBM formulary positioning, CMS Medicare coverage decisions (Part B and Part D), Medicaid managed care contracts, hospital GPO pricing, and P&T committee listings at individual health systems. Each layer has its own evidence requirements, decision cadence, and commercial leverage points.

    The Inflation Reduction Act of 2022 has reshaped commercial strategy for products with significant Medicare exposure. IRA Medicare price negotiation (effective January 2026 for the first cohort of 10 drugs) creates MFPs that materially affect commercial rebate strategies and PBM formulary positioning. BioNixus conducts IRA impact research: payer strategy studies, physician communication research, and PBM formulary intelligence in the post-IRA environment.

    ICER (Institute for Clinical and Economic Review) assessments carry significant payer influence despite no statutory authority — PBM formulary decisions increasingly cite ICER evidence. BioNixus conducts pre-ICER evidence strategy research and post-assessment payer impact studies to help access teams respond effectively to ICER's growing influence on US formulary dynamics.

    Why pharmaceutical teams choose BioNixus in the USA

    • ✓Specialist in pharma and healthcare research — not a generalist panel company running healthcare as a sideline
    • ✓Verified US physician and specialist networks across major AMCs and community IDN practices
    • ✓IRB-compliant protocols and HIPAA-compliant data handling built into every project
    • ✓Deep FDA, CMS, PBM, and IRA regulatory context built into study design
    • ✓Dual quantitative and qualitative capability in one team — no subcontracting
    • ✓HEOR and RWE program design compatible with FDA, CMS, and ICER evidence requirements
    • ✓15+ years of healthcare research experience across 17+ countries
    • ✓Global benchmarking capability — US studies connect to UK, EU5, Brazil, Saudi Arabia, UAE

    Related US healthcare research resources

    US pharmaceutical market researchUSA healthcare market reportTop healthcare MR companies USA 2026Top market research companies USA 2026Healthcare market research UAEHealthcare market research Saudi Arabia

    FAQs

    Who is the best healthcare market research company in the USA?

    BioNixus is a leading healthcare market research company in the USA, delivering IRB-compliant HCP surveys, KOL mapping, and payer landscape research aligned with FDA, CMS, and PBM requirements. BioNixus combines primary research depth with physician access across major US academic medical centres and specialist community networks.

    What does a healthcare market research company in the USA typically do?

    A healthcare market research company in the USA designs and executes studies covering physician prescribing behavior, payer and formulary access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the US market.

    How is US healthcare market research different from other markets?

    The US is uniquely decentralized: FDA approval does not guarantee market access. Commercial outcomes depend on PBM formulary placement (UnitedHealth/Optum, CVS/Caremark, Express Scripts), Medicare Part B/D CMS coverage decisions, and hospital GPO and P&T committee listings — each with distinct evidence requirements. IRA Medicare price negotiation (effective 2026) has added further strategic complexity for products with significant Medicare exposure.

    What therapeutic areas does BioNixus cover in US healthcare research?

    BioNixus covers oncology, immunology and biologics, cardiovascular, diabetes and metabolic (including GLP-1/IRA dynamics), rare disease and gene therapy, respiratory, infectious disease, neurology, and consumer health across the US market.

    Can BioNixus recruit US physicians and KOLs?

    Yes. BioNixus maintains physician and specialist networks across major US academic medical centres (Mayo Clinic, Cleveland Clinic, Johns Hopkins, UCSF, MSKCC, MGH) and community IDN networks. For scarce specialties such as oncology or rare disease, we recruit through NCI cancer centre networks and rare disease specialist directories.

    What is the typical timeline for healthcare market research in the USA?

    Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area, IRB review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-AMC recruitment may require extended planning timelines.

    Does BioNixus conduct HIPAA-compliant patient research in the USA?

    Yes. BioNixus designs and executes US patient research in compliance with HIPAA/HITECH data privacy standards and IRB/OHRP ethics requirements under 45 CFR Part 46. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling.

    Can US healthcare research connect to global benchmarking programs?

    Yes. US modules can run with comparable cells in the UK, EU5 (Germany, France, Italy, Spain), Brazil, Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner.

    Discuss your United States pharmaceutical research strategy

    Our team supports pharmaceutical companies with decision-ready insights across MENA, UK, and Europe using quantitative and qualitative methodologies.

    Request a proposalEmail us

    US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323

    Request a proposal